Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 2
1985 4
1987 3
1989 3
1990 3
1991 13
1992 3
1993 4
1994 2
1995 6
1996 7
1997 12
1998 10
1999 12
2000 4
2001 7
2002 9
2003 8
2004 6
2005 6
2006 8
2007 3
2008 9
2009 13
2010 12
2011 7
2012 9
2013 11
2014 7
2015 8
2016 13
2017 18
2018 17
2019 19
2020 22
2021 27
2022 22
2023 28
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

349 results

Results by year

Filters applied: . Clear all
Page 1
Novel role for epalrestat: protecting against NLRP3 inflammasome-driven NASH by targeting aldose reductase.
Shi W, Xu G, Gao Y, Zhao J, Liu T, Zhao J, Yang H, Wei Z, Li H, Xu AL, Bai Z, Xiao X. Shi W, et al. J Transl Med. 2023 Oct 7;21(1):700. doi: 10.1186/s12967-023-04380-4. J Transl Med. 2023. PMID: 37805545 Free PMC article.
Next, MCD-induced NASH models were used to evaluate the therapeutic effects of epalrestat in vivo. In addition, to evaluate the safety of epalrestat in vivo, mice were gavaged with epalrestat daily for 14 days. ...Importantly, epalrestat exerts its inh …
Next, MCD-induced NASH models were used to evaluate the therapeutic effects of epalrestat in vivo. In addition, to evaluate the safet …
Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus.
Steele JW, Faulds D, Goa KL. Steele JW, et al. Drugs Aging. 1993 Nov-Dec;3(6):532-55. doi: 10.2165/00002512-199303060-00007. Drugs Aging. 1993. PMID: 8312678 Review.
Epalrestat is a carboxylic acid derivative which inhibits aldose reductase, an enzyme of the sorbitol (polyol) pathway. ...Comparisons with other aldose reductase inhibitors are also required to fully determine the role of epalrestat. The suggested ability of epa …
Epalrestat is a carboxylic acid derivative which inhibits aldose reductase, an enzyme of the sorbitol (polyol) pathway. ...Comparison …
Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
Ramirez MA, Borja NL. Ramirez MA, et al. Pharmacotherapy. 2008 May;28(5):646-55. doi: 10.1592/phco.28.5.646. Pharmacotherapy. 2008. PMID: 18447661 Review.
Unlike the current treatment options for diabetic neuropathy, epalrestat may affect or delay progression of the underlying disease process. ...Epalrestat may serve as a new therapeutic option to prevent or slow the progression of diabetic neuropathy. ...
Unlike the current treatment options for diabetic neuropathy, epalrestat may affect or delay progression of the underlying disease pr …
[Epalrestat].
Hotta N. Hotta N. Nihon Rinsho. 1997 Nov;55 Suppl:204-11. Nihon Rinsho. 1997. PMID: 9434468 Review. Japanese. No abstract available.
Alpha lipoic acid combined with epalrestat: a therapeutic option for patients with diabetic peripheral neuropathy.
Wang X, Lin H, Xu S, Jin Y, Zhang R. Wang X, et al. Drug Des Devel Ther. 2018 Sep 7;12:2827-2840. doi: 10.2147/DDDT.S168878. eCollection 2018. Drug Des Devel Ther. 2018. PMID: 30233145 Free PMC article. Review.
BACKGROUND: Alpha lipoic acid (ALA), a type of antioxidant, is used in combination with epalrestat in the treatment of diabetic peripheral neuropathy (DPN). ...CONCLUSION: ALA combined with epalrestat is an effective option for DPN patients. Future large-sample RCTs …
BACKGROUND: Alpha lipoic acid (ALA), a type of antioxidant, is used in combination with epalrestat in the treatment of diabetic perip …
Epalrestat suppresses inflammatory response in lipopolysaccharide-stimulated RAW264.7 cells.
Sato K, Tatsunami R, Wakame K. Sato K, et al. Allergol Immunopathol (Madr). 2021 Sep 1;49(5):1-8. doi: 10.15586/aei.v49i5.102. eCollection 2021. Allergol Immunopathol (Madr). 2021. PMID: 34476915
The purpose of the present study was to determine whether epalrestat (EPS), which is used for the treatment of diabetic neuropathy, suppresses inflammatory response in LPS-stimulated RAW264.7 cells. ...
The purpose of the present study was to determine whether epalrestat (EPS), which is used for the treatment of diabetic neuropathy, s …
Epalrestat suppresses cadmium-induced cytotoxicity through Nrf2 in endothelial cells.
Tatsunami R, Sato K, Murao Y, Yama K, Yu Y, Ohno S, Tampo Y. Tatsunami R, et al. Exp Ther Med. 2021 Apr;21(4):393. doi: 10.3892/etm.2021.9824. Epub 2021 Feb 24. Exp Ther Med. 2021. PMID: 33680115 Free PMC article.
The purpose of the present study was to determine whether epalrestat (EPS), which is used for the treatment of diabetic neuropathy, protects against Cd-induced cytotoxicity in bovine aortic endothelial cells (BAECs). ...
The purpose of the present study was to determine whether epalrestat (EPS), which is used for the treatment of diabetic neuropathy, p …
Moving toward a new horizon for the aldose reductase inhibitor epalrestat to treat drug-resistant cancer.
Bailly C. Bailly C. Eur J Pharmacol. 2022 Sep 15;931:175191. doi: 10.1016/j.ejphar.2022.175191. Epub 2022 Aug 11. Eur J Pharmacol. 2022. PMID: 35964660 Review.
Epalrestat (EPA) is a potent inhibitor of aldose reductases AKR1B1 and AKR1B10, used for decades in Japan for the treatment of diabetic peripheral neuropathy. ...
Epalrestat (EPA) is a potent inhibitor of aldose reductases AKR1B1 and AKR1B10, used for decades in Japan for the treatment of diabet …
Epalrestat, an Aldose Reductase Inhibitor, Restores Erectile Function in Streptozocin-induced Diabetic Rats.
Yang BB, Hong ZW, Zhang Z, Yu W, Song T, Zhu LL, Jiang HS, Chen GT, Chen Y, Dai YT. Yang BB, et al. Int J Impot Res. 2019 Mar;31(2):97-104. doi: 10.1038/s41443-018-0075-x. Epub 2018 Sep 13. Int J Impot Res. 2019. PMID: 30214006 Free PMC article.
Epalrestat, an aldose reductase inhibitor (ARI), was adopted to improve the function of peripheral nerves in diabetic patients. The aim of this study was to investigate whether epalrestat could restore the erectile function of diabetic erectile dysfunction using a r …
Epalrestat, an aldose reductase inhibitor (ARI), was adopted to improve the function of peripheral nerves in diabetic patients. The a …
The Aldose Reductase Inhibitor Epalrestat Maintains Blood-Brain Barrier Integrity by Enhancing Endothelial Cell Function during Cerebral Ischemia.
Zhang T, Wu J, Yao X, Zhang Y, Wang Y, Han Y, Wu Y, Xu Z, Lan J, Han S, Zou H, Sun Q, Wang D, Zhang J, Wang G. Zhang T, et al. Mol Neurobiol. 2023 Jul;60(7):3741-3757. doi: 10.1007/s12035-023-03304-z. Epub 2023 Mar 20. Mol Neurobiol. 2023. PMID: 36940077 Free PMC article.
Thus, we hypothesized that the protective effect of epalrestat is mainly related to regulating the survival of BMVECs and tight junction protein levels after cerebral ischemia. To test this hypothesis, a mouse model of cerebral ischemia was established by permanent middle …
Thus, we hypothesized that the protective effect of epalrestat is mainly related to regulating the survival of BMVECs and tight junct …
349 results

Searches related to "epalrestat"